Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials.
about
Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophreniaClozapine: a review of clinical practice guidelines and prescribing trendsClozapine augmentation for treatment-resistant schizoaffective disorderClozapine for psychotic disorders in adults with intellectual disabilitiesPharmacological interventions for clozapine-induced sinus tachycardiaAripiprazole for people with schizophrenia whose illness has been partially responsive to clozapineClozapine combined with different antipsychotic drugs for treatment resistant schizophreniaPharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature reviewPharmacologic treatment of schizophreniaCurrent perspectives in the treatment of resistant schizophreniaThe use of amisulpride in the treatment of acute psychosisComparison of Classical and Clozapine Treatment on Schizophrenia Using Positive and Negative Syndrome Scale of Schizophrenia (PANSS) and SPECT ImagingPharmacological interventions for clozapine-induced sinus tachycardiaPrevalence and Predictors of Clozapine-Associated Constipation: A Systematic Review and Meta-AnalysisNeuroimaging findings in treatment-resistant schizophrenia: A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophreniaTreatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychoticsClozapine: an effective treatment for seriously violent and psychopathic men with antisocial personality disorder in a UK high-security hospitalCosts of new atypical antipsychotic agents for schizophrenia: does unrestricted access reduce hospital utilization?A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacyResults of phase 3 of the CATIE schizophrenia trial.Identification of blood-based molecular signatures for prediction of response and relapse in schizophrenia patientsCost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia.Modern antipsychotic drugs: a critical overviewThe Six-Point Dial of Treatment: A Useful Framework for Novice Therapists.Recent advances in understanding schizophreniaComparison of clozapine response for inpatients in the research setting versus routine clinical practiceClozapine: Current perspective.A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia.Efficacy and tolerability of quetiapine versus haloperidol in first-episode schizophrenia: a randomized clinical trial.Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.Mental illness that is difficult to classify: a case studyWhat CATIE found: results from the schizophrenia trial.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.Co-occurrence of Intermetamorphosis and Frégoli Syndrome in Schizophrenia: A Case ReportRoutine outcomes monitoring to support improving care for schizophrenia: report from the VA Mental Health QUERI.Levomepromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial.Pharmacotherapy for treatment-resistant schizophrenia.
P2860
Q21260279-A846B0F5-6814-4A94-852A-495CAB69ABF0Q21260307-914F81D7-25F7-4038-955C-2AEAC17BC0EEQ24186084-5662ACE1-F685-4733-B6F8-52C4772DAB96Q24187048-D652D030-8C40-40FE-AC05-EA7BFD0F5680Q24187704-BACBD42A-55C8-46D0-AA59-6F2178A11931Q24198295-6FEDAFA2-0175-4742-9CE2-6C0E0D887DB7Q24240093-A8D4C1BC-77FD-497B-9EE2-7C1442230D3EQ24598636-2E3D774A-0D64-402F-9932-5485E03FCB15Q24604457-369B818E-9925-42CF-9E92-AF0F0A7F0D52Q24650594-958684E0-79B5-4256-8B61-FBE2AC513989Q24683055-E2C6A0AD-1AFB-40C1-957F-D1C1B370E03DQ24810335-FDD234BA-2A92-4AA2-A38C-A01FF005FAECQ26471506-0446C371-5E31-4FD7-8535-D4130BC22236Q26748476-B6FC59D9-176B-4D4F-A7CC-77D7B6BAFFDFQ27026382-F81AA056-C9CD-4509-ABAC-7CF8F21CD35BQ28079065-A8DA5ED5-2114-4C2E-AD0F-40DA7A24CFEFQ28237349-1F0C7CE2-B8CE-4B60-A4C7-315C04E4FDE0Q30484093-3FE19902-84D8-43DF-B14C-DD3C47857A3CQ30485065-AEB4A9EA-E15D-48C9-A157-E2D928CF2732Q30487308-7CD789D8-F9E3-4A0D-8570-966488BE8AF8Q30511886-7987A35D-347B-49B5-A7C4-55357DBF5F21Q30590794-5CF59D29-0C9D-470B-9D0E-B126A93DC68AQ33223628-1E3FC523-8E3D-49C8-B666-F9B0503B5DA9Q33235110-23D6D772-0047-4AE6-A79B-952F4E854A3BQ33853390-59E38A59-867B-44C5-B85E-0B53F648CC4AQ33920656-0CBA729B-2AF8-4427-B367-0D997F001E2CQ33942094-4B5F5E69-E967-4DD1-B662-1A39E4316451Q33994937-0F30E631-7F0F-49BB-9096-71FEFDD4F0E1Q34021447-1BF7C332-E683-4D39-B484-63D9CB19E62DQ34224372-A1FA984B-1315-4E31-8014-E7DCE5BE887DQ34242783-69C5C49F-1A21-452B-9DDF-10D500F11722Q34274859-6DF0F741-91EE-421C-A891-BFF62FE7C2A5Q34338202-858B286D-8EB0-48D8-98AD-095CB3E9BAC9Q34533126-D032A5DE-A037-4A85-A254-35271FF04A52Q34591378-14D2CD8E-C748-40C4-A2D0-BAFCA8883BE5Q34640811-03EEEA4B-78F3-4557-B365-6C60A88C5076Q34642034-3C248D6F-8186-4829-91BD-D31902DC9004Q34680925-16E50C6A-3934-4A61-9CF9-735D6CB86232Q34716524-D9F65292-9AFD-4E9F-874E-FC94FC40BE7AQ34879109-1F1AF931-6EFC-42DD-BA2E-2F112FAB6534
P2860
Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials.
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Effectiveness of second-genera ...... analysis of randomized trials.
@ast
Effectiveness of second-genera ...... analysis of randomized trials.
@en
Effectiveness of second-genera ...... analysis of randomized trials.
@nl
type
label
Effectiveness of second-genera ...... analysis of randomized trials.
@ast
Effectiveness of second-genera ...... analysis of randomized trials.
@en
Effectiveness of second-genera ...... analysis of randomized trials.
@nl
prefLabel
Effectiveness of second-genera ...... analysis of randomized trials.
@ast
Effectiveness of second-genera ...... analysis of randomized trials.
@en
Effectiveness of second-genera ...... analysis of randomized trials.
@nl
P2093
P921
P1476
Effectiveness of second-genera ...... analysis of randomized trials.
@en
P2093
P304
P356
10.1176/APPI.AJP.158.4.518
P407
P577
2001-04-01T00:00:00Z